Darolutamide and hormone therapy for frail men with advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs, darolutamide and hormone therapy, for men with prostate cancer that has spread and who are considered frail. The goal is to see if this treatment can improve outcomes for this group of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have prostate cancer that has spread to your bones, lymph nodes, or other organs (confirmed by a scan).
- You have some signs of frailty, such as needing help with daily activities, recent weight loss, or a low body mass index.
- You have not had any treatment for your metastatic prostate cancer, or only had hormone therapy for up to 45 days.
- You are willing to participate in the IRONMAN registry study, which collects information about men with metastatic prostate cancer.
- If you are sexually active with a partner who could become pregnant, you agree to use two forms of birth control, including a condom.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
This trial tests darolutamide (a hormone blocker pill) with or without standard hormone therapy given before surgery for high-risk prostate cancer. The goal is to see if this combination can shrink the cancer and improve outcomes before the prostate is removed.
This study tests a combination of three treatments (darolutamide, docetaxel, and hormone therapy) given before surgery for men with locally advanced prostate cancer that hasn't spread. The goal is to see if this approach is safe and effective in shrinking the cancer before surgery.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.